Abiant, Inc. Announces Close on First Phase of Investment Round
Chicago, ILLINOIS - - October 1, 2007 - - Abiant, Inc., an Illinois based company specializing in
advanced bio-imaging to accelerate and improve drug development and disease diagnosis,
announces the successful closing of a $600,000 private placement. Lead investor Heartland Angels,
an angel network specializing in early-stage technology, syndicated the round with Kettering Medical
Center and other participants. Abiant has developed partnerships with large pharmaceutical
companies and with academic collaborators. The company has obtained an exclusive license from
New York University School of Medicine to image processing technology that has enabled the early and
accurate identification of dementias.
“We are excited about supporting a technology that will change the way we monitor CNS drug effects in
the clinical testing process," said Ron Kirschner, M.D., President of Heartland Angels.
Ed Maier, owner of the Maier Consulting Group and a former Senior Partner with Arthur Andersen, and
Rick Mace, Vice President, Clinical Services Division of Kettering Medical Center, have joined Abiant’s
Board of Directors as part of this Offering.
Dawn Matthews, President and CEO of Abiant, said “With this financing, we are adding two valuable
strategic partners and the resources to expand the application of our imaging technology. We are
eager to continue the progress created by the dedication and shared vision of our team, customers,
and stakeholders.” O.B. Parrish, Chairman of Abiant’s Board, added “This financing provides Abiant
with the opportunity to grow and capitalize on its technology.”
Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker of
drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, can be used to accelerate or reduce risk of decision making
in both drug development and disease treatment. The Company’s focus areas include the central
nervous system, oncology, and inflammation. Further information can be found at www.abiant-imaging.
Forward Looking Statements
This press release may contain "forward-looking" statements identified by words such as "will,"
"continue," "grow," and "capitalize." There are a number of important factors that could cause Abiant's
results to differ materially from those indicated by these forward-looking statements.
|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030